We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

News · September 21, 2022

ESMO 2022: Overall Survival Improved With Abemaciclib and Trastuzumab With or Without Fulvestrant in Advanced Breast Cancer

Phase II monarcHER trial reveals improved survival with combination therapies in women with HR-positive, HER2-positive advanced breast cancer

PracticeUpdate Editorial Team

 

Further Reading